Niagen Bioscience, Inc. current report, 11 August 2016

SEC Filing Summary: ChromaDex Corporation (Form 8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on August 11, 2016. The filing serves to announce the Company's earnings results for the second quarter ended July 2, 2016. The detailed financial data is contained within the attached press release (Exhibit 99.1), which is not included in the text of this filing.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1).

Material Changes

The filing does not contain specific comparative data or material changes versus the prior period. It solely references the issuance of the Q2 2016 earnings press release.

Guidance, Outlook, and Risks

The filing text does not include management commentary, forward-looking guidance, risk factors, or contingencies. It notes that the information in Item 2.02 and the exhibit is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Review the attached Exhibit 99.1 (Press Release dated August 11, 2016) for actual Q2 2016 financial figures.
  • Verify the specific revenue and net income numbers reported in the press release.
  • Check for any updated full-year guidance provided in the press release.
  • Confirm the filing status of the earnings data as "furnished" rather than "filed" under Section 18 of the Exchange Act.